# Chai Discovery **Source:** https://geo.sig.ai/brands/chai-discovery **Vertical:** Healthcare Tech **Subcategory:** AI Molecular Discovery **Tier:** Challenger **Website:** chaidiscovery.com **Last Updated:** 2026-04-14 ## Summary AI molecular discovery unicorn ($1.3B valuation). 100x improvement in de novo antibody design success. Backed by OpenAI. Eli Lilly partnership. Founded 2023, SF. $225M+ raised. ## Company Overview Chai Discovery is an AI-driven molecular discovery company founded in 2024 and headquartered in San Francisco. The company was spun out of research conducted by scientists with backgrounds at leading computational biology and AI organizations, with the founding mission of applying the latest advances in generative AI to accelerate drug discovery — particularly the historically difficult challenge of designing novel antibodies and small molecules from scratch rather than optimizing known chemical scaffolds.\n\nChai's core technology is a foundation model for molecular structure prediction and de novo design that operates across proteins, small molecules, nucleic acids, and their complexes. The company's flagship research achievement is a reported 100-fold improvement in de novo antibody design success rates, enabling the generation of functional antibody candidates without requiring extensive experimental screening campaigns. Chai Discovery has established a research partnership with Eli Lilly, one of the world's largest pharmaceutical companies, to apply its platform to therapeutic target programs. The company is backed by OpenAI, reflecting the deep connection between large-scale AI modeling techniques and the biological sequence-structure-function prediction task.\n\nChai Discovery reached a $1.3 billion valuation within its first year of operation, an exceptionally rapid ascent reflecting the strategic premium investors place on AI-native molecular discovery platforms. The company operates at the intersection of structural biology, generative AI, and therapeutic development, competing with platforms like Isomorphic Labs, Recursion, and Insilico Medicine in the race to demonstrate AI-designed drugs in human clinical trials. ## Frequently Asked Questions ### What does Chai Discovery do? AI foundation models for predicting and designing biochemical molecules — a computer-aided design suite for drug discovery. ### What is Chai 2? Zero-shot generative platform achieving 100x improvement in de novo antibody design success rates. ### What is Chai Discovery's valuation? $1.3B (unicorn) after $130M Series B (Dec 2025). $225M+ total from OpenAI, Oak HC/FT, General Catalyst. ### Who founded Chai Discovery? Jack Dent, Jacques Boitreaud, Matthew McPartlon, Joshua Meier (from OpenAI, Meta FAIR, Stripe, Google X) in 2023. ### What partnerships does Chai have? Eli Lilly and other major pharmaceutical companies for AI molecular design applications. ### What is the Chai-1 model and how does it differ from AlphaFold? Chai-1 is Iambic's — and later Chai Discovery's — foundation model for predicting the structure of biological complexes including proteins, nucleic acids, small molecules, and their interactions simultaneously. Unlike AlphaFold 2 (which predicts single protein structures) or AlphaFold 3 (which handles complexes but is not freely available for commercial use), Chai-1 was released open-source in 2024 under terms permitting research use and was accessible via API for commercial drug discovery applications. ### What is Chai Discovery's Chai 2 platform? Chai 2 is Chai Discovery's generative design platform that goes beyond structure prediction to create novel antibody sequences with desired binding properties from scratch. The system demonstrated a 100-fold improvement in de novo antibody design success rates in internal benchmarks — generating antibodies that actually bind target proteins without starting from known binders. This zero-shot generative capability is what attracted Eli Lilly as a partner and made Chai a unicorn within two years of founding. ### How is Chai Discovery different from Isomorphic Labs or AbSci? Chai Discovery focuses specifically on antibody and protein complex design using its proprietary foundation models, while Isomorphic Labs (DeepMind spin-out) focuses on small molecule drug design using AlphaFold-derived models. AbSci combines AI antibody design with biomanufacturing capabilities. Chai's differentiator is its open-source strategy for research tools (building scientific credibility) paired with a proprietary commercial platform for pharma partnerships, enabling it to simultaneously build academic validation and generate enterprise revenue. ## Tags b2b, healthtech, saas --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*